Novel Therapies in Primary Biliary Cholangitis: What Is in the Pipeline?
- PMID: 36270727
- DOI: 10.1016/j.cld.2022.06.013
Novel Therapies in Primary Biliary Cholangitis: What Is in the Pipeline?
Abstract
Primary biliary cholangitis is a chronic autoimmune disease characterized by inflammation and the progressive destruction of small intrahepatic bile ducts. Current first-line treatment includes ursodeoxycholic acid; however, a significant number of patients have an inadequate response to therapy. These patients are at risk of liver failure requiring liver transplantation and experience a poor quality of life due to refractory symptoms. This manuscript aims to shed light on the current and prospective treatment options that may slow disease progression and improve these patients' symptoms.
Keywords: Farnesoid X receptor; Immunomodulators; Novel; OCA; Peroxisome proliferator-activated receptor agonist; Primary biliary cholangitis; Therapy; Ursodeoxycholic acid.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure K Buchanan-Peart has nothing to disclose. C Levy advises and has received grants from Cymabay, Gilead, Genfit, Intercept, Genkyotex, GSK, Mirum, Pliant, Target RWE, and Cara; advises for Escient and Teva; and has received grants from NGM, Novartis, Zydus, Mitsubishi, and Alnylam.
Similar articles
-
Obeticholic acid for the treatment of primary biliary cholangitis.Expert Opin Pharmacother. 2016 Sep;17(13):1809-15. doi: 10.1080/14656566.2016.1218471. Epub 2016 Aug 9. Expert Opin Pharmacother. 2016. PMID: 27468093 Review.
-
What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?Dig Dis. 2017;35(4):359-366. doi: 10.1159/000467547. Epub 2017 May 3. Dig Dis. 2017. PMID: 28468009 Review.
-
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.Expert Rev Clin Immunol. 2017 Dec;13(12):1121-1131. doi: 10.1080/1744666X.2017.1391093. Epub 2017 Nov 9. Expert Rev Clin Immunol. 2017. PMID: 28994348 Review.
-
[Advances in the treatment of primary biliary cholangitis].Zhonghua Gan Zang Bing Za Zhi. 2017 Nov 20;25(11):805-809. doi: 10.3760/cma.j.issn.1007-3418.2017.11.002. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 29325272 Chinese.
-
Current Treatment Options for Primary Biliary Cholangitis.Clin Liver Dis. 2018 Aug;22(3):481-500. doi: 10.1016/j.cld.2018.03.003. Epub 2018 May 19. Clin Liver Dis. 2018. PMID: 30259848 Review.
Cited by
-
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?Front Immunol. 2023 May 30;14:1184252. doi: 10.3389/fimmu.2023.1184252. eCollection 2023. Front Immunol. 2023. PMID: 37325634 Free PMC article. Review.
-
Understanding fatigue and pruritus in primary biliary cholangitis.Clin Liver Dis (Hoboken). 2024 May 31;23(1):e0216. doi: 10.1097/CLD.0000000000000216. eCollection 2024 Jan-Jun. Clin Liver Dis (Hoboken). 2024. PMID: 38831766 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
